Twist Bioscience wants to shrink DNA synthesis to smaller and smaller volumes, possibly enabling DNA storage, according to the San Francisco Chronicle.
The company, which was founded in 2016, said it would use the funding to further develop its core gene synthesis platform.
DNA Script has acquired an exclusive license to a novel DNA building block for use in enzymatic DNA synthesis.
Maravai was launched in 2014 by private equity firm GTCR in partnership with two former Gen-Probe executives.
The Boston-based synthetic biology company will use the proceeds to grow Bioworks3, its new organism foundry, and to expand into new markets.
Oxford will license its SnapFast platform to Twist, to provide it with a range of application-specific expression vectors it can use to clone synthesized DNA.
Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.
The yet-to-be-named entity will draw on the partners' respective resources in synthetic biology and plant and agricultural products.
The Series A round included investments from Illumina Ventures, Merck KGaA's M Ventures, Sofinnova Partners, Kurma Partners, and Idinvest Partners.
The two companies will work in tandem to provide customers worldwide with access to genes up to 70 kilobases in length.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.